Cargando…
Evolving Treatment of Advanced Hepatocellular Carcinoma in the Asia–Pacific Region: A Review and Multidisciplinary Expert Opinion
SIMPLE SUMMARY: For years, the systemic therapies sorafenib and lenvatinib have represented standard of care for first-line treatment of advanced hepatocellular carcinoma (HCC). The recent approval of atezolizumab in combination with bevacizumab heralded the arrival of immunotherapy for first-line t...
Autores principales: | Ogasawara, Sadahisa, Choo, Su-Pin, Li, Jiang-Tao, Yoo, Changhoon, Wang, Bruce, Lee, Dee, Chow, Pierce K. H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197840/ https://www.ncbi.nlm.nih.gov/pubmed/34071818 http://dx.doi.org/10.3390/cancers13112626 |
Ejemplares similares
-
Potential Impact of IMbrave150 Results in the Evolving Treatment Landscape of Advanced Hepatocellular Carcinoma: A Multidisciplinary Expert Opinion
por: Kulik, Laura, et al.
Publicado: (2020) -
Gadoxetate-Enhanced MRI as a Diagnostic Tool in the Management of Hepatocellular Carcinoma: Report from a 2020 Asia-Pacific Multidisciplinary Expert Meeting
por: Tan, Cher Heng, et al.
Publicado: (2022) -
Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region
por: Zhu, Ran Xu, et al.
Publicado: (2016) -
Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
por: Omata, Masao, et al.
Publicado: (2017) -
Harm reduction in Asia and the Pacific: an evolving public health response
por: Crofts, Nick, et al.
Publicado: (2015)